Open AccessIntrigue: Phase III Study of Ripretinib Versus Sunitinib in Advanced Gastrointestinal Stromal Tumor After Imatinib
Author(s) -
John Nemunaitis,
Sebastian Bauer,
JeanYves Blay,
Khalil Choucair,
Hans Gelderblom,
Suzanne George,
Patrick Schöffski,
Margaret von Mehren,
John Zalcberg,
Haroun Achour,
Rodrigo RuizSoto,
Michael C. Heinrich
Publication year - 2019
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2019-0633
Subject(s) - sunitinib , medicine , imatinib , tyrosine kinase inhibitor , gist , pdgfra , stromal tumor , clinical endpoint , oncology , stromal cell , imatinib mesylate , clinical trial , phases of clinical research , tyrosine kinase , regorafenib , cancer research , cancer , receptor , colorectal cancer , myeloid leukemia
Ripretinib (DCC-2618) is a novel, type II tyrosine switch control inhibitor designed to broadly inhibit activating and drug-resistant mutations in KIT and PDGFRA. Ripretinib has emerged as a promising investigational agent for the treatment of gastrointestinal stromal tumor owing to targeted inhibition of secondary resistance mutations that may develop following treatment with prior line(s) of tyrosine kinase inhibitors. Here we describe the rationale and design of intrigue (NCT03673501), a global, randomized (1:1), open-label, Phase III study comparing the safety and efficacy of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor following imatinib. The primary end point is progression-free survival and key secondary objectives include objective response rate and overall survival. Clinical Trial Registration: NCT03673501
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom